Wall Street brokerages expect Xenon Pharmaceuticals Inc (NASDAQ:XENE) to announce ($0.36) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Xenon Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.37) and the highest estimate coming in at ($0.35). Xenon Pharmaceuticals reported earnings of ($0.21) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 71.4%. The business is expected to announce its next quarterly earnings report on Tuesday, May 14th.

On average, analysts expect that Xenon Pharmaceuticals will report full-year earnings of ($1.62) per share for the current year, with EPS estimates ranging from ($1.74) to ($1.50). For the next financial year, analysts forecast that the firm will report earnings of ($1.62) per share, with EPS estimates ranging from ($1.68) to ($1.55). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Xenon Pharmaceuticals.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.08.

Several equities research analysts have recently commented on XENE shares. Stifel Nicolaus restated a “buy” rating and issued a $18.00 target price (down previously from $21.00) on shares of Xenon Pharmaceuticals in a research note on Friday, March 29th. Zacks Investment Research downgraded shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 23rd. Finally, ValuEngine upgraded shares of Xenon Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 2nd. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $14.58.

Xenon Pharmaceuticals stock remained flat at $$8.66 on Monday. 38,011 shares of the company’s stock traded hands, compared to its average volume of 99,533. The company has a market cap of $218.58 million, a price-to-earnings ratio of -6.51 and a beta of 1.75. The company has a debt-to-equity ratio of 0.16, a current ratio of 29.48 and a quick ratio of 29.48. Xenon Pharmaceuticals has a 12-month low of $4.50 and a 12-month high of $15.92.

Several large investors have recently modified their holdings of the company. Northern Trust Corp boosted its stake in shares of Xenon Pharmaceuticals by 18.9% in the 4th quarter. Northern Trust Corp now owns 12,246 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 1,948 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in Xenon Pharmaceuticals during the 3rd quarter worth about $111,000. Scotia Capital Inc. lifted its position in Xenon Pharmaceuticals by 16.8% during the 4th quarter. Scotia Capital Inc. now owns 66,704 shares of the biopharmaceutical company’s stock worth $421,000 after buying an additional 9,618 shares in the last quarter. Virtu Financial LLC acquired a new position in Xenon Pharmaceuticals during the 4th quarter worth about $80,000. Finally, Geode Capital Management LLC acquired a new position in Xenon Pharmaceuticals during the 4th quarter worth about $88,000. Institutional investors own 69.15% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in phase II clinical trail for the treatment of epilepsy.

Read More: SEC Filing

Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.